# IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency

> **NCT00228852** · PHASE1,PHASE2 · COMPLETED · sponsor: **Emory University**

## Conditions studied

- T-Cell Immune Deficiency Diseases
- Severe Combined Immunodeficiency

## Interventions

- **DRUG:** Busulfan, Fludarabine and ATG

## Key facts

- **NCT ID:** NCT00228852
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2006-11
- **Target enrollment:** — (—)
- **Last updated:** 2009-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00228852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00228852, "IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00228852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*